The U.S. Food and Drug Administration (FDA) has experienced significant upheaval, with major workforce reductions, leadership turnover, and policy reversals continuing into 2026, according to an April 15 report from BioSpace.
The agency's recent instability has raised concerns within the biopharma industry about regulatory consistency and the future direction of drug approvals. The turmoil began in 2025 when the FDA cut approximately 3,500 staff members, leading to delays in new drug application reviews. Additionally, there were multiple reversals of guidance that resulted in unexpected rejections for some companies.
Leadership changes have been especially notable. Five different directors led the Center for Research and Drug Evaluation over a short period after a series of high-profile departures. The resignation of longtime Center for Biologics Evaluation and Research head Peter Marks was followed by a drop in the S&P biotech index XBI. Although Richard Pazdur briefly accepted the role as CDER director, he soon retired as well. As of late last year, Tracy Beth Høeg was serving as acting CDER chief.
Despite these challenges, the FDA approved 56 novel therapies in 2025—a slight decrease from previous years—but also diverged from its advisory committees' recommendations more frequently than before. Policy activity remained high; more than fifteen new policies or guidance documents were issued last year alone. Notably, new vaccine regulations prompted Moderna to scale back certain efforts after receiving conflicting signals from regulators.
Communication around these policies has shifted as well: "Unlike in previous years...the agency has been communicating policy through editorials...often without a public comment period and typically lacking important details," Chad Landmon said to BioSpace.
Looking ahead into 2026, industry experts anticipate further guidance on cell and gene therapies as well as rare diseases while keeping watch on expedited approval pathways that could shape future product launches.
